Get access

Medical and surgical treatment of neonatal hemochromatosis: Single center experience

Authors


Massimo Asolati, Dallas VA Medical Center, Surgical Service (MC 112), 4500 S. Lancaster Road, Dallas, TX 75208, USA
Tel.: 214-857-1800
Fax: 214-857-1891
E-mail: m_asolati@hotmail.com

Abstract

Abstract:  NH is a rare disorder of iron storage in newborns resulting in rapid liver failure. Outcomes are dismal with 20–30% survival. We report our experience in eight children with NH. Assessment of liver function included admission PT and serum levels of FV and FVII. Medical treatment (antioxidant cocktail) was started in all patients, with chelation therapy in six. Of these six, three survived with medical treatment alone. The other three underwent liver transplant. One died 158 days after transplant to sepsis: two are well more than five yr after transplant. The two neonates who did not receive chelation therapy, died to multi-organ failure and sepsis. In summary, five children (62.5%) survived long-term. In the three transplanted, one- and five-yr-survival was 66%. Older children with compromised synthetic liver function (FVII levels ≤ 15%) required liver replacement for survival. Early referral to a tertiary care center is essential to increase survival of these children with a rare and otherwise fatal disease. Single center experience of children with NH is here presented. Potentials for survival improvement with of medical and surgical treatment are examined.

Ancillary